Immune therapy for EBV-related lymphoproliferative diseases
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed Epstein-Barr virus (EBV) infection with high levels of EBV in your blood or tissues.
- You may have chronic active EBV (CAEBV) or EBV-related lymphoproliferative disease (EBV-LPD), including after an organ or stem cell transplant.
- Your age must be between 2 and 70 years old (or between 18 and 70 if you are a transplant recipient).
- Your liver, kidney, and heart function must be adequate, and your blood counts must meet minimum levels.
- You cannot have active serious infections, autoimmune disease, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This early-phase trial tests lab-made “memory” immune T cells that target Epstein-Barr virus (EBV). It may help people whose EBV infection has caused lymphomas or serious complications after a transplant.
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Hear when a new CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.